Access here alternative investment news about Antios Therapeutics Raises $75M In A Series B-1 Funding To Advance Clinical Programs For Hbv
Venture Capital

Antios Therapeutics Raises $75M In A Series B-1 Funding To Advance Clinical Programs For Hbv

by prnewswire.com posted 3weeks ago 25 views
MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of a $75 million Series B-1 financing. The...

In this article